The Aftermath of a 'Miracle Cure' for a Rare Cancer

In 2001, Gleevec was approved as a treatment for chronic myelogenous leukemia. It was a revelation for personalized medicine—with harrowing financial repercussions that persist today.

from Wired https://ift.tt/9BENlwn

Comments

Popular posts from this blog

Tableau launches new enterprise plans, big data tools

Galaxy Book 3 leak spills the beans on the latest Samsung laptops